Last year, Exelixis paid $7.5 million for a license to an ADC developed by Iconic Therapeutics – called ICON-2 – which ... positive melanoma – and Daiichi Sankyo-partnered hypertension ...

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive ...

AstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, worth up to $6 billion. The deal covers DS-1062, Daiichi Sankyo’s proprietary ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

At close: March 21 at 3:59:05 PM EDT ...

After hours: March 21 at 7:52:18 PM EDT Loading Chart for ICON ...

UK app developers are essential partners in crafting a user-friendly, high-quality mobile app that can effectively showcase your products and services. A well-designed app not only enhances your brand ...